HCV drug combo linked to side effects after liver transplant

05/16/2013 | Aidsmap

Adding telaprevir to pegylated interferon and ribavirin increased sustained viral response rates among difficult-to-treat liver transplant recipients, but adverse events were also common, according to findings from six U.S. centers presented at EASL 2013.

View Full Article in:

Aidsmap

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA